Dataset: Total Body Metabolic Tumor Response in ALK Positive Non-Small Cell Lung Cancer Patients Treated with ALK Inhibition
Kerner, G. (Creator), Koole, M. J. B. (Creator), Bongaerts, A. H. H. (Creator), Pruim, J. (Creator) & Groen, H. (Creator), University of Groningen, 23-Apr-2016
Patients with advanced EML4/ALK positive NSCLC treated with crizotinib were studied with 18F-FDG PET/CT at baseline and after six weeks of treatment. During and after treatment patients underwent PET/CT until progression of disease was determined. If they were eligible for additional treatment (local treatment or systemic treatment with a second generation ALK inhibitor), PET/CT was repeated to assess tumor response again until disease progression was determined.
18F-FDG PET/CT was performed prior to and after 6 weeks of crizotinib treatment. Tumor response on CT was classified with RECIST 1.1, while 18F-FDG PET response was assessed according to the 1999 EORTC recommendations and PERCIST criteria. Agreement was assessed using McNemars test. During follow-up, patients received additional PET/CT during crizotinib treatment and second generation ALK inhibition. We assessed whether PET was able to detect progression earlier then CT.
|Date made available||23-Apr-2016|
|Publisher||University of Groningen|
|Access to the dataset||Open|
- Nuclear Medicine, Radioology, Organ Imaging, Oncology, EML4/ALK, NSCLC, Crizotinib, 18F-FDG PET/CT, Treatment Response
Keywords on Datasets
Total Body Metabolic Tumor Response in ALK Positive Non-Small Cell Lung Cancer Patients Treated with ALK InhibitionKerner, G. S. M. A., Koole, M. J. B., Bongaerts, A. H. H., Pruim, J., Groen, H. J. M. & CTMM Air Force Consortium, 3-May-2016, In : PLoS ONE. 11, 5, 10 p., e0149955.
Research output: Contribution to journal › Article › Academic › peer-review